0001374690--12-31Q3falsehttp://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember6284P2Y3 years0001374690us-gaap:RetainedEarningsMember2021-12-310001374690us-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2020-05-282020-05-280001374690lrmr:WakeForestUniversityHealthSciencesMembersrt:MaximumMember2016-11-300001374690lrmr:MTSHealthPartnersMemberus-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2020-05-282020-05-280001374690srt:MaximumMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember2023-09-3000013746902022-01-012022-03-310001374690us-gaap:ComputerEquipmentMember2023-09-300001374690us-gaap:LeaseholdImprovementsMember2023-09-300001374690us-gaap:CommonStockMember2022-06-300001374690us-gaap:ResearchAndDevelopmentExpenseMemberlrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember2022-01-012022-12-3100013746902023-07-012023-09-300001374690srt:MaximumMemberlrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember2019-12-112019-12-110001374690lrmr:OfficeAndLabMemberstpr:PA2021-08-092021-08-090001374690lrmr:EmployeesMemberus-gaap:RestrictedStockUnitsRSUMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember2023-01-012023-09-300001374690us-gaap:CommonStockMember2022-07-012022-09-300001374690lrmr:EmployeesMemberus-gaap:CommonStockMemberlrmr:FirstAnniversaryMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember2023-01-012023-09-300001374690us-gaap:RetainedEarningsMember2023-06-300001374690us-gaap:PrivatePlacementMember2020-05-280001374690lrmr:TwoThousandTwentyEquityIncentivePlanMember2023-01-012023-09-300001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001374690us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001374690us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2022-12-310001374690us-gaap:MoneyMarketFundsMember2022-12-310001374690us-gaap:MoneyMarketFundsMember2023-09-300001374690lrmr:TwoThousandTwentyEquityIncentivePlanMember2022-12-3100013746902021-12-310001374690us-gaap:AdditionalPaidInCapitalMember2023-06-300001374690us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001374690us-gaap:RetainedEarningsMember2023-07-012023-09-300001374690country:MAlrmr:OfficeMember2020-05-282020-05-280001374690country:MAlrmr:FirstSubleaseYearMemberlrmr:OfficeSubleaseMember2020-10-270001374690us-gaap:CommonStockMember2022-03-310001374690us-gaap:FairValueInputsLevel2Member2022-12-310001374690us-gaap:CorporateBondSecuritiesMember2023-09-300001374690lrmr:InducementStockMember2023-09-300001374690country:MAus-gaap:LetterOfCreditMemberlrmr:OfficeSubleaseMemberlrmr:SixthSubleaseYearMember2020-10-2700013746902023-09-3000013746902023-08-112023-08-110001374690us-gaap:AdditionalPaidInCapitalMember2021-12-3100013746902023-06-300001374690us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001374690lrmr:TwoThousandTwentyEquityIncentivePlanMember2023-09-300001374690us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001374690lrmr:FromExerciseOfWarrantsMember2023-08-1200013746902022-07-012022-09-300001374690us-gaap:EquipmentMember2022-12-310001374690us-gaap:RetainedEarningsMember2023-04-012023-06-300001374690us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001374690us-gaap:CommonStockMember2023-03-3100013746902023-03-310001374690us-gaap:LeaseholdImprovementsMember2022-12-310001374690us-gaap:CommonStockMember2023-07-012023-09-3000013746902023-04-012023-06-300001374690us-gaap:RetainedEarningsMember2022-12-310001374690us-gaap:FairValueInputsLevel1Member2023-09-300001374690lrmr:OfficeAndLabMemberstpr:PA2023-01-012023-01-310001374690us-gaap:AdditionalPaidInCapitalMember2023-09-300001374690us-gaap:CommonStockMember2022-12-3100013746902023-01-012023-09-300001374690us-gaap:RetainedEarningsMember2022-07-012022-09-300001374690us-gaap:RetainedEarningsMember2023-03-310001374690lrmr:OfficeAndLabMemberstpr:PA2018-11-050001374690stpr:PAlrmr:OfficeMember2023-03-090001374690us-gaap:FurnitureAndFixturesMember2022-12-310001374690us-gaap:RetainedEarningsMember2023-09-300001374690us-gaap:RetainedEarningsMember2023-01-012023-03-310001374690us-gaap:AdditionalPaidInCapitalMember2022-06-300001374690srt:MaximumMemberlrmr:IndianaUniversityResearchAndTechnologyCorporationMember2016-11-300001374690us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001374690us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001374690srt:MaximumMemberus-gaap:CommonStockMemberlrmr:AtTheMarketEquityOfferingProgramMember2022-11-012022-11-100001374690us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-09-3000013746902022-06-300001374690us-gaap:USTreasurySecuritiesMember2023-09-300001374690us-gaap:AdditionalPaidInCapitalMember2023-03-310001374690us-gaap:EquipmentMember2023-09-3000013746902022-09-300001374690country:MAus-gaap:LetterOfCreditMemberlrmr:OfficeMember2020-05-280001374690us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-09-300001374690lrmr:InducementStockMember2023-01-012023-09-300001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001374690stpr:PAlrmr:OfficeMember2023-03-092023-03-0900013746902022-01-012022-12-310001374690lrmr:OfficeAndLabMemberstpr:PA2020-08-042020-08-040001374690us-gaap:RetainedEarningsMember2022-09-300001374690us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-09-300001374690us-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2020-05-280001374690country:MAus-gaap:LetterOfCreditMemberlrmr:FirstSubleaseYearMemberlrmr:OfficeSubleaseMember2020-10-270001374690us-gaap:CommonStockMemberlrmr:AtTheMarketEquityOfferingProgramMember2022-11-100001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001374690us-gaap:CommonStockMember2023-06-300001374690us-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2023-08-012023-08-3100013746902022-04-012022-06-300001374690us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001374690lrmr:AdditionalOfficeMemberstpr:PAus-gaap:SubsequentEventMember2023-10-3100013746902022-03-310001374690us-gaap:RetainedEarningsMember2022-04-012022-06-300001374690srt:MaximumMember2023-07-012023-09-300001374690us-gaap:CommonStockMemberlrmr:AtTheMarketEquityOfferingProgramMember2022-11-012022-11-100001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001374690lrmr:OfficeAndLabMemberstpr:PA2018-11-052018-11-050001374690us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001374690stpr:PAlrmr:OfficeMember2019-08-082019-08-0800013746902022-12-310001374690us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001374690lrmr:WakeForestUniversityHealthSciencesMember2016-11-300001374690us-gaap:RestrictedStockUnitsRSUMember2022-12-310001374690lrmr:FirstAnniversaryMemberlrmr:InducementStockMember2023-01-012023-09-300001374690us-gaap:RetainedEarningsMember2022-03-310001374690us-gaap:CommonStockMember2022-09-012022-09-300001374690lrmr:TwoThousandTwentyEquityIncentivePlanMember2022-01-012022-01-010001374690lrmr:IndianaUniversityResearchAndTechnologyCorporationMember2016-11-300001374690us-gaap:AdditionalPaidInCapitalMember2022-09-300001374690us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001374690us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001374690us-gaap:RetainedEarningsMember2022-01-012022-03-310001374690us-gaap:PrivatePlacementMember2020-05-282020-05-280001374690us-gaap:CommonStockMember2021-12-310001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001374690us-gaap:RetainedEarningsMember2022-06-3000013746902022-01-012022-09-300001374690lrmr:CommonStockEquivalentsMember2022-01-012022-09-300001374690us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-3000013746902023-01-012023-03-310001374690us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001374690us-gaap:ComputerEquipmentMember2022-12-310001374690us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2022-12-310001374690lrmr:EmployeesMemberus-gaap:CommonStockMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember2023-01-012023-09-300001374690us-gaap:FairValueInputsLevel2Member2023-09-300001374690lrmr:FinalSubleaseYearMembercountry:MAlrmr:OfficeSubleaseMember2020-10-270001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001374690us-gaap:FurnitureAndFixturesMember2023-09-300001374690us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001374690stpr:PAlrmr:OfficeMember2023-09-300001374690us-gaap:AdditionalPaidInCapitalMember2022-03-310001374690us-gaap:AdditionalPaidInCapitalMember2022-12-310001374690us-gaap:CommonStockMember2023-09-300001374690us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001374690us-gaap:FairValueInputsLevel1Member2022-12-310001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-3000013746902023-11-120001374690us-gaap:CommonStockMember2022-09-300001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001374690lrmr:TwoThousandTwentyEquityIncentivePlanMember2023-01-012023-01-010001374690stpr:PAlrmr:OfficeMember2019-08-080001374690us-gaap:CommonStockMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember2023-09-300001374690us-gaap:RestrictedStockUnitsRSUMember2023-09-300001374690lrmr:CommonStockEquivalentsMember2023-01-012023-09-300001374690country:MAlrmr:OfficeSubleaseMember2020-10-272020-10-270001374690srt:MaximumMember2022-07-012022-09-30xbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesiso4217:USD

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ____

Commission File Number: 001-36510

LARIMAR THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

20-3857670

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

 

Three Bala Plaza East, Suite 506

19004

Bala Cynwyd, PA

(Zip Code)

(Address of principal executive offices)

 

 

(844) 511-9056

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

LRMR

The Nasdaq Global Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

As of November 12, 2023, there were 43,905,903 shares of the registrant’s Common Stock, $0.001 par value per share, outstanding.

 


 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Statements made in this Quarterly Report on Form 10-Q that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements discuss our business, operations and financial performance and conditions, as well as our plans, objectives and expectations for our business operations and financial performance and condition. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “positioned,” “potential,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements that “we believe” or similar statements reflect our beliefs and opinions on the relevant subject only. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business.

You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:

uncertainties in obtaining successful non-clinical or clinical results that reliably and meaningfully demonstrate safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration (“FDA”), European Medicines Agency and other comparable regulatory authorities for marketing approval for nomlabofusp (nomlabofusp is now the new International Nonproprietary Name and the United States Adopted Name for CTI-1601) or any other product candidate that we may develop in the future and unexpected costs that may result therefrom;
delays in patient recruitment for our clinical trials (including as a result of the impact of FDA approval of competitive products for the treatment of Friedreich's ataxia ("FA"), and/or the impact of other clinical trials of competitive products), delays as a result of clinical and non-clinical results and/or FDA's request for additional information or studies (whether clinical or non-clinical), changes in clinical protocols, regulatory restrictions, including additional clinical holds, and milestones for nomlabofusp;
our ability to initiate our open label extension trial;
uncertainties associated with the clinical development and regulatory approval for nomlabofusp or any other product candidate that we may develop in the future, including potential delays in the commencement, enrollment and completion of clinical trials;
the difficulties and expenses associated with obtaining and maintaining regulatory approval for nomlabofusp or any other product candidate we may develop in the future, and the indication and labeling under any such approval;
how long we can continue to fund our operations with our existing cash, cash equivalents and marketable securities and our estimates regarding future results of operations, financial position, research and development costs, capital requirements and our access and needs for additional financing;
our ability, and the ability of third-party manufacturers we engage, to optimize and scale nomlabofusp or any other product candidate’s manufacturing process and to manufacture sufficient quantities of clinical supplies, and, if approved, commercial supplies of nomlabofusp or any other product candidate that we may develop in the future and our ability to maintain our relationships, and contracts with our key vendors and to identify and contract with alternate or secondary key vendors;
our ability to realize any value from nomlabofusp and/or any other product candidate we may develop in the future in light of inherent risks and difficulties involved in successfully bringing product candidates to market and the risk that the product candidates, if approved, will not achieve broad market acceptance;
our ability to comply with regulatory requirements applicable to our business and other regulatory developments in the United States and other countries;

 


 

the size and growth of the potential markets for nomlabofusp, if approved, or any other product candidate that we may develop in the future, the rate and degree of market acceptance of nomlabofusp or any other product candidate, if approved, that we may develop in the future and our ability to serve those markets;
given competing therapies and products for the treatment of FA, our ability to obtain and maintain designations or eligibility for expedited regulatory programs, and to commercialize current and future candidates, if approved, (including the impact of potential barriers to entry if a competitor is able to establish a strong market position before we are able to commercialize our products);
our ability to obtain and maintain patent protection and defend our intellectual property rights against third-parties;
the performance and compliance with the rules and regulations of the FDA (and all other regulatory authorities) of third parties upon which we depend, including third-party contract research organizations ("CROs"), consultants, and third-party suppliers, manufacturers, distributors, and logistics providers;
our ability to recruit and retain key scientific, technical, commercial, and management personnel and to retain our executive officers;
our ability to maintain proper functionality and security of our internal computer and information systems and prevent or avoid cyber-attacks, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption;
the extent to which geopolitical tensions including regional conflicts around the world, adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability and the ability of the U.S. government to manage federal debt limits, health epidemics, unforeseen emergencies and other outbreaks of communicable diseases could disrupt our operations, the operations of third parties on which we rely or the operations of regulatory agencies we interact with in the development of nomlabofusp; and
the potential impact of healthcare reform in the United States, including the Inflation Reduction Act of 2022, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures.

These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate. Management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements may not be achieved or occur at all. The factors that could cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K filed on March 14, 2023 and our Quarterly Reports on Form 10-Q filed on May 15, 2023 and on August 10, 2023. All forward-looking statements are applicable only as of the date on which they were made and, except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of any unanticipated events. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

 


 

Larimar Therapeutics, Inc.

INDEX

 

 

 

Page

 

 

 

PART I - FINANCIAL INFORMATION

 

 

 

 

 

Item 1

 

Financial Statements (unaudited)

 

3

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022

 

3

 

 

 

 

 

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022

 

4

 

 

 

 

 

 

 

Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended September 30, 2023 and 2022

 

5

 

 

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022

 

7

 

 

 

 

 

 

 

Notes to Condensed Consolidated Financial Statements

 

8

 

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

20

 

 

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

29

 

 

 

 

 

Item 4.

 

Controls and Procedures

 

29

 

 

 

 

 

PART II - OTHER INFORMATION

 

 

 

 

 

Item 1.

 

Legal Proceedings

 

30

 

 

 

 

 

Item 1A.

 

Risk Factors

 

30

 

 

 

 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

30

 

 

 

 

 

Item 3.

Defaults Upon Senior Securities

 

30

 

 

 

 

 

Item 4.

Mine Safety Disclosures

 

30

 

 

 

 

 

Item 5.

 

Other Information

 

30

 

 

 

 

 

Item 6.

 

Exhibits

 

31

 

 

 

 

 

Signatures

 

32

 

2


 

PART I-FINANCIAL INFORMATION

Item 1. Financial Statements

LARIMAR THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

38,721

 

 

$

26,825

 

Marketable securities

 

 

56,869

 

 

 

91,603

 

Prepaid expenses and other current assets

 

 

2,890

 

 

 

2,311

 

Total current assets

 

 

98,480

 

 

 

120,739

 

Property and equipment, net

 

 

601

 

 

 

831

 

Operating lease right-of-use assets

 

 

2,898

 

 

 

2,858

 

Restricted cash

 

 

1,339

 

 

 

1,339

 

Other assets

 

 

634

 

 

 

638

 

Total assets

 

$

103,952

 

 

$

126,405

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

756

 

 

$

1,686

 

Accrued expenses

 

 

5,094

 

 

 

8,408

 

Operating lease liabilities, current

 

 

708

 

 

 

611

 

Total current liabilities

 

 

6,558

 

 

 

10,705

 

Operating lease liabilities

 

 

4,682

 

 

 

4,797

 

Total liabilities

 

 

11,240

 

 

 

15,502

 

Commitments and contingencies (See Note 8)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock; $0.001 par value per share; 5,000,000 shares authorized
   as of September 30, 2023 and December 31, 2022;
no shares issued and
   outstanding as of September 30, 2023 and December 31, 2022

 

 

 

 

 

 

Common stock, $0.001 par value per share; 115,000,000 shares
   authorized as of September 30, 2023 and December 31, 2022;
   
43,905,903 and 43,269,200 shares issued and outstanding as of
   September 30, 2023 and December 31, 2022, respectively

 

 

43

 

 

 

43

 

Additional paid-in capital

 

 

268,223

 

 

 

262,496

 

Accumulated deficit

 

 

(175,561

)

 

 

(151,605

)

Accumulated other comprehensive gain (loss)

 

 

7

 

 

 

(31

)

Total stockholders’ equity

 

 

92,712

 

 

 

110,903

 

Total liabilities and stockholders’ equity

 

$

103,952

 

 

$

126,405

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3


 

LARIMAR THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

6,585

 

 

$

5,582

 

 

$

17,022

 

 

$

17,032

 

General and administrative

 

 

3,754

 

 

 

2,931

 

 

 

10,574

 

 

 

9,055

 

Total operating expenses

 

 

10,339

 

 

 

8,513

 

 

 

27,596

 

 

 

26,087

 

Loss from operations

 

 

(10,339

)

 

 

(8,513

)

 

 

(27,596

)

 

 

(26,087

)

Other income, net

 

 

1,275

 

 

 

193

 

 

 

3,640

 

 

 

157

 

Net loss

 

$

(9,064

)

 

$

(8,320

)

 

$

(23,956

)

 

$

(25,930

)

Net loss per share, basic and diluted

 

$

(0.21

)

 

$

(0.37

)

 

$

(0.55

)

 

$

(1.32

)

Weighted average common shares outstanding, basic and diluted

 

 

43,903,738

 

 

 

22,228,228

 

 

 

43,899,670

 

 

 

19,649,558

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(9,064

)

 

$

(8,320

)

 

$

(23,956

)

 

$

(25,930

)

Other comprehensive gain (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on marketable securities

 

 

(5

)

 

 

17

 

 

 

38

 

 

 

(40

)

Total other comprehensive gain (loss)

 

 

(5

)

 

 

17

 

 

 

38

 

 

 

(40

)

Total comprehensive loss

 

$

(9,069

)

 

$

(8,303

)

 

$

(23,918

)

 

$

(25,970

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4


 

LARIMAR THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN

STOCKHOLDERS’ EQUITY

(In thousands, except share data)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Other

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders’

 

 

 

Shares

 

 

Par Value

 

 

Capital

 

 

Deficit

 

 

Gain (Loss)

 

 

Equity

 

Balances as of December 31, 2022

 

 

43,269,200

 

 

$

43

 

 

$

262,496

 

 

$

(151,605

)

 

$

(31

)

 

$

110,903

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

1,833

 

 

 

 

 

 

 

 

 

1,833

 

Unrealized gain on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31

 

 

 

31

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(6,526

)

 

 

 

 

 

(6,526

)

Balances as of March 31, 2023

 

 

43,269,200

 

 

$

43

 

 

$

264,329

 

 

$

(158,131

)

 

$

 

 

$

106,241

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

2,043

 

 

 

 

 

 

 

 

 

2,043

 

Unrealized gain on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

12

 

 

 

12

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(8,366

)

 

 

 

 

 

(8,366

)

Balances as of June 30, 2023

 

 

43,269,200

 

 

$

43

 

 

$

266,372

 

 

$

(166,497

)

 

$

12

 

 

$

99,930

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

1,821

 

 

 

 

 

 

 

 

 

1,821

 

Exercise of stock options

 

 

8,300

 

 

 

 

 

 

24

 

 

 

 

 

 

 

 

 

24

 

Exercise of warrants

 

 

628,403

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

6

 

Unrealized loss on marketable debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5

)

 

 

(5

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(9,064

)

 

 

 

 

 

(9,064

)

Balances as of September 30, 2023

 

 

43,905,903

 

 

$

43

 

 

$

268,223

 

 

$

(175,561

)

 

$

7

 

 

$

92,712

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5


 

LARIMAR THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN

STOCKHOLDERS’ EQUITY

(In thousands, except share data)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Other

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders’

 

 

 

Shares

 

 

Par Value

 

 

Capital

 

 

Deficit

 

 

Loss

 

 

Equity

 

Balances as of December 31, 2021

 

 

17,710,450

 

 

$

18

 

 

$

180,645

 

 

$

(116,250

)

 

$

 

 

$

64,413

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

1,635

 

 

 

 

 

 

 

 

 

1,635

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(8,943

)

 

 

 

 

 

(8,943

)

Balances as of March 31, 2022

 

 

17,710,450

 

 

$

18

 

 

$

182,280

 

 

$

(125,193

)

 

$

 

 

$

57,105

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

1,675

 

 

 

 

 

 

 

 

 

1,675

 

Unrealized loss on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(57

)

 

 

(57

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(8,667

)

 

 

 

 

 

(8,667

)

Balances as of June 30, 2022

 

 

17,710,450

 

 

$

18

 

 

$

183,955

 

 

$

(133,860

)

 

$

(57

)

 

$

50,056

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

1,666

 

 

 

 

 

 

 

 

 

1,666

 

Issuance of Common Stock, net

 

 

25,558,750

 

 

 

25

 

 

 

75,218

 

 

 

 

 

 

 

 

 

75,243

 

Unrealized gain on marketable debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

17

 

 

 

17

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(8,320

)

 

 

 

 

 

(8,320

)

Balances as of September 30, 2022

 

 

43,269,200

 

 

$

43

 

 

$

260,839

 

 

$

(142,180

)

 

$

(40

)

 

$

118,662

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6


 

LARIMAR THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

2022

 

Cash flows from operating activities:

 

 

 

 

 

Net loss

 

$

(23,956

)

 

$

(25,930

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Stock-based compensation expense

 

 

5,697

 

 

 

4,976

 

Non-cash lease expense

 

 

(58

)

 

 

(28

)

Depreciation expense

 

 

230

 

 

 

240

 

Amortization of premium on marketable securities

 

 

(1,210

)

 

 

(66

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(579

)

 

 

(321

)

Accounts payable

 

 

(930

)

 

 

(891

)

Accrued expenses

 

 

(3,314

)

 

 

1,097

 

Other assets

 

 

4

 

 

 

26

 

Net cash used in operating activities:

 

 

(24,116

)

 

 

(20,897

)

Cash flows from investing activities:

 

 

 

 

 

Purchase of property and equipment

 

 

 

 

 

(100

)

Purchase of marketable securities

 

 

(66,268

)

 

 

(61,626

)

Maturities and sales of marketable securities

 

 

102,250

 

 

 

23,000

 

Net cash provided by (used in) investing activities

 

 

35,982

 

 

 

(38,726

)

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from issuance of equity securities, net of issuance costs

 

 

 

 

 

75,573

 

Proceeds from exercise of stock options and warrants

 

 

30

 

 

 

 

Net cash provided by financing activities

 

 

30

 

 

 

75,573

 

Net increase in cash, cash equivalents and restricted cash

 

 

11,896

 

 

 

15,950

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

28,164

 

 

 

71,436

 

Cash, cash equivalents and restricted cash at end of period

 

$

40,060

 

 

$

87,386

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

Offering costs included in accounts payable and accrued expense

 

$

 

 

$

330

 

Leased asset obtained in exchange for new operating lease liability

 

$

452

 

 

$

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7


 

LARIMAR THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.
Description of Business and Basis of Presentation

Larimar Therapeutics, Inc., together with its subsidiary (the “Company” or “Larimar”), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar's lead product candidate, nomlabofusp (nomlabofusp is the new International Nonproprietary Name ("INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich’s ataxia ("FA"). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.

The Company has completed two phase 1 studies of nomlabofusp and the first cohort of a Phase 2 study in patients with FA. In May 2021, after reporting positive top-line data from the Company’s Phase 1 FA program, the U.S. Food and Drug Administration (“FDA”) placed a clinical hold on the Company’s nomlabofusp clinical program after the Company notified the FDA of mortalities at the highest dose levels of a 26-week non-human primate toxicology study that was designed to support extended dosing of patients with nomlabofusp. In August 2022, the Company submitted a complete response to the clinical hold following a Type C Meeting with the FDA, and proposed as nomlabofusp's next clinical trial a Phase 2, four-week, dose exploration study in FA patients starting at the lower dose levels tested in the Company’s Phase 1 multiple-ascending dose clinical trial. In September 2022, the FDA lifted its full clinical hold on the nomlabofusp program and imposed a partial clinical hold.

In May 2023, the Company announced top-line data from its completed 25 mg cohort of a Phase 2, four-week, dose exploration trial of nomlabofusp in patients with FA and provided a complete response to the FDA in June 2023, which included unblinded safety, pharmacokinetic ("PK"), and pharmacodynamic ("PD") data from the Phase 2 trial’s completed 25 mg cohort. Data from the completed 25 mg cohort (n = 13) indicated that nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14 (the final day of daily dosing in the trial).

In June 2023, the Company met with the FDA. Following that meeting, the Company submitted a complete response to the FDA’s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial’s completed 25 mg cohort.

In July 2023, the FDA cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of nomlabofusp in patients with FA to proceed to a 50 mg cohort in which participants are dosed daily for the first 14 days, and then every other day until day 28. Additionally, the FDA cleared for initiation the Company’s open label extension (“OLE”) trial in which participants are currently expected to receive 25 mg of nomlabofusp daily.

In November 2023, the Company completed enrollment and dosing of the 50 mg cohort of its Phase 2 double-blind dose exploration trial evaluating nomlabofusp for the treatment of FA. Treatment assignment of the fully enrolled cohort of 15 participants remains blinded as they complete the follow up period. Participants were dosed daily with nomlabofusp or placebo for the first 14 days, and then every other day until day 28. Based on blinded Phase 2 observations during the dosing period, there were no serious adverse events for either the nomlabofusp or placebo groups. Top-line Phase 2 safety, pharmacokinetics and frataxin data from skin and buccal cells from both the 25 mg and 50 mg cohorts are now expected in the first quarter of 2024 refined from the first half of 2024. Initiation of additional U.S. clinical trials or potential further dose escalation in these trials is contingent on FDA review of Phase 2 data from the 50 mg cohort due to the partial clinical hold.

In November 2023, the Company reaffirmed guidance for initiation of the OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. Participants who complete treatment in the Phase 2 dose exploration trial, or who previously completed a prior clinical trial of nomlabofusp are potentially eligible for the OLE. The OLE will evaluate the safety and tolerability and PK and measures of frataxin levels in peripheral tissues as well as other exploratory PD markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. Clinical measures collected during the trial will be compared to a data from a synthetic control arm derived from participants in the Friedreich’s Ataxia Clinical Outcome Measures Study (FACOMS) database. The OLE trial is expected to begin in the first quarter of 2024 with interim data expected in the fourth quarter of 2024.

 

8


 

The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales.
 

Basis of Presentation

The condensed consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying condensed consolidated financial statements have been prepared in conformity with Generally Accepted Accounting Principles ("GAAP").

The condensed consolidated balance sheet as of December 31, 2022 was derived from the Company’s audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2023 and the Company’s Quarterly Reports on Form 10-Q filed with the SEC on May 15, 2023 and August 10, 2023.

In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of September 30, 2023, condensed consolidated results of operations for the three and nine months ended September 30, 2023 and 2022 and condensed consolidated statement of cash flows for the nine months ended September 30, 2023 and 2022 have been made. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023.

Liquidity and Capital Resources

The Company’s condensed consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of $24.0 million and $25.9 million for the nine months ended September 30, 2023 and 2022, respectively. In addition, as of September 30, 2023, the Company had an accumulated deficit of $175.6 million. The Company expects to continue to generate operating losses for the foreseeable future. As of September 30, 2023, the Company had approximately $95.6 million of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.

The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents, marketable securities and restricted cash upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.

In accordance with Accounting Standards Update (“ASU”) No. 2014-15, "Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. As of the issuance date of these condensed consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital

9


 

expenditure requirements, for at least twelve months from the issuance of these condensed consolidated financial statements into the first quarter of 2025. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.

The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.

There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.

If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion or pre commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.

2.
Summary of Significant Accounting Policies

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.

Research and Development Costs

Costs associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, stock-based compensation, facility-related expenses, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities, and clinical trials as well as to manufacture clinical trial materials, depreciation and other costs. The Company recognizes external research and development

10


 

costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers.

Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.

Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.

Patent Costs

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

Stock-Based Compensation

The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.

The Company classifies stock-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.

Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.

Net Loss Per Share

Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company’s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of six thousand two hundred and eighty-four dollars. Accordingly, subsequent to August 11, 2023 the 628,403 shares issued upon the exercise of these warrants are included in issued and outstanding common stock.

Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.

The Company excluded 5,100,997 and 3,136,776 common stock equivalents outstanding as of September 30, 2023 and 2022, respectively, from the computation of diluted net loss per share for the three and nine months ended

11


 

September 30, 2023 and 2022 because they had an anti-dilutive impact due to the net loss incurred for the periods presented.

Recently Issued and Adopted Accounting Pronouncements

From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the condensed consolidated results of operations, cash flows or financial position.

3.
Fair Value Measurements and Marketable Securities

Fair Value Measurements

The Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 are measured in accordance with the standards of ASC 820, "Fair Value Measurements and Disclosures", which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

 

Level – 1

Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

 

Level – 2

Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

 

Level – 3

Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The Company’s financial instruments consist primarily of cash, cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of September 30, 2023 and December 31, 2022 were considered representative of their fair values due to their short term to maturity.

12


 

The following tables summarize the Company’s cash equivalents and marketable securities as of September 30, 2023 and December 31, 2022.

 

 

 

Total

 

 

Quoted
Prices in
Active
Markets
(Level 1)

 

 

Significant
Other
Observable
Inputs
(Level 2)

 

 

Significant
Unobservable
Inputs
(Level 3)

 

 

 

(in thousands)

 

September 30, 2023

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds invested in government securities

 

$

34,232

 

 

$

34,232

 

 

$

 

 

$

 

             Total cash equivalents

 

 

34,232

 

 

 

34,232